Amerise Biosciences Ltd (531681)
🎯 Key Takeaways
- Amerise Biosciences Ltd appears to be in a distressed or dormant phase, with no meaningful revenue generation and persistent negative financial metrics. The company has not reported any operational activity in recent quarters, and its financials reflect minimal asset base and negative reserves.
- ⚠️ 1) Persistent lack of revenue and operational activity raises concerns about business viability. 2) Negative reserves and minimal equity suggest long-
📖 The Story
Amerise Biosciences Ltd appears to be in a distressed or dormant phase, with no meaningful revenue generation and persistent negative financial metrics. The company has not reported any operational activity in recent quarters, and its financials reflect minimal asset base and negative reserves. There is no evidence of a turnaround strategy or growth initiatives currently underway.
📰 What's Happening
The company has not announced any new orders, expansions, or strategic initiatives in recent filings. Management has not provided forward guidance or discussed operational recovery plans in the latest disclosures. The business appears to be non-operational, with no active revenue streams reported since at least September 2025.
Source: Stock Announcements
📊 Quarterly Results (₹ Cr)
| Metric | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 |
| Operating Profit | -0 | 0 | 0 | -0 |
| OPM % | -57.1% | 25.0% | 75.0% | — |
| Net Profit | -0 | 0 | 0 | -0 |
| EPS | ₹-0.01 | ₹0.00 | ₹0.01 | ₹-0.01 |
Revenue has remained stagnant at ₹0 across all recent quarters, with alternating periods of minor profitability and loss. The company posted a net profit of ₹0 in December 2025 and March 2026, but recorded losses in September 2025 and June 2026. Operating performance shows no upward trend, and EPS has fluctuated between ₹0.01 and ₹-0.01 without any underlying business momentum.
🔮 Management Outlook & What's Next
There is no available forward guidance or strategic outlook from management in the latest filings. The company has not provided any commentary on future business plans, revenue targets, or operational revival. The absence of guidance suggests either a lack of clarity or deliberate silence on future prospects.
Extracted from official company announcements. Not StockFin.ai's opinion.
🏦 Balance Sheet (₹ Cr)
| Item | Mar 2025 | Mar 2025 | Mar 2026 | Mar 2026 |
|---|---|---|---|---|
| Equity Capital | 7 | 7 | 7 | 7 |
| Reserves | -1 | -1 | -1 | -1 |
| Borrowings | 0 | 0 | 0 | 0 |
| Total Liabilities | 5 | 8 | 8 | 7 |
| Fixed Assets | 0 | 0 | 0 | 0 |
| Investments | 2 | 2 | 4 | 4 |
| Total Assets | 5 | 8 | 8 | 7 |
The balance sheet shows a minimal equity base of ₹7 crore with negative reserves, indicating accumulated losses. Total assets remain flat at approximately ₹7-8 crore with no debt or liabilities. There is no evidence of capital investment or strategic asset buildup, suggesting the company is not actively scaling or reinvesting.
💰 Cash Flow Statement (₹ Cr)
| Item | Mar 2025 |
|---|---|
| Operating | +3 |
| Investing | -3 |
| Financing | 0 |
| Net Cash Flow | +0 |
👥 Shareholding Pattern
| Category | Q2FY26 | Q3FY26 | Q4FY26 | Q1FY27 |
|---|---|---|---|---|
| Promoters | 0.0% | 0.0% | 0.0% | 0.0% |
| FII | 0.0% | 0.0% | 0.0% | 0.0% |
| DII | 0.0% | 0.0% | 0.0% | 0.0% |
| Public | 72.0% | 72.0% | 72.0% | 69.9% |
| # Shareholders | 35,676 | 35,180 | 34,519 | 33,848 |
Public shareholding has slightly declined over the past year, from 72.04% to 69.9%, while the number of shareholders has decreased. There is no activity from institutional investors (FII/DII) or promoters. The stock is widely dispersed among retail investors, but with no significant accumulation or reduction signals from major players.
⚖️ Peer Comparison — Miscellaneous
| Company | MCap (₹ Cr) | P/E | ROCE | ROE | D/E |
|---|---|---|---|---|---|
| GMRAIRPORT | 99,096 | 204.0 | 12.1% | -23.5% | -13.08 |
| NBCC | 23,180 | 31.3 | 41.3% | 30.9% | 0.00 |
| CMPDI | 16,508 | 29.9 | 32.4% | 24.2% | 0.00 |
| IGIL | 14,747 | 24.2 | 56.1% | 41.0% | 0.00 |
| HORIZONIND | 13,933 | — | — | — | 1.22 |
| RITES | 10,492 | 25.2 | 23.5% | 17.5% | 0.00 |
| INOXGREEN | 6,703 | 53.7 | 9.4% | 6.7% | 0.10 |
| RAIN | 6,555 | 12.2 | 12.0% | 8.9% | 1.21 |
| SIS | 6,068 | 41.4 | 8.0% | 5.8% | 0.56 |
| THOMASCOOK | 5,064 | 22.3 | 15.8% | 9.2% | 0.10 |
🔗 Peer Stock Analyses
⚠️ Risk Factors
1) Persistent lack of revenue and operational activity raises concerns about business viability. 2) Negative reserves and minimal equity suggest long-term financial erosion. 3) No management communication on revival strategy increases uncertainty. 4) High retail investor dispersion with no institutional interest may lead to low liquidity and price volatility.
🧠 Analyst's Read
Amerise Biosciences appears to be a financially weakened entity with no active operations or clear path forward. Investors should monitor for any future announcements regarding business resumption or capital restructuring, but current indicators suggest limited upside or strategic direction.
Based on filing content and financial data. Not a recommendation.
Read the full analysis
Quarterly trends, balance sheet, cash flow, peer comparison, and AI insights — sign up free to unlock.
Sign Up Free — Unlock Full Analysis2 free AI queries per day.
Data sourced from stock announcements. Analysis generated by StockFin.ai.
For informational purposes only — not investment advice. Updated 2026-09-01.
Editorial & Data Transparency Notice
This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.
📡 Get AI alerts for your stocks — summarized by AI daily
Set up your AI Radar — pick stocks, get daily email summaries of new filings.
Set up AI Radar — FreeFree account · 2 AI queries/day
© 2026 StockFin.ai — AI-powered Indian stock research
About · Privacy Policy · Terms of Service · Pricing
Today's Announcements · Screener · Insights · AI Chat
Data provided by CMOTS Internet Technologies Pvt Ltd